Loading clinical trials...

A Registry for Participants With Chronic Hypoparathyroidism | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

A Registry for Participants With Chronic Hypoparathyroidism

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism

NCT01922440•Takeda

View on ClinicalTrials.gov

Summary

The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH\[1-84\]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice. Participants will be treated according to their clinic's standard practice determined by the treating doctors. Each participant will fill out a study questionnaire during a routine doctor visit.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants diagnosed with chronic hypoparathyroidism, that is, hypoparathyroidism with a duration of longer than 6 months, including:
•1. Adult participants (greater than or equal to \[\>=\] 18 years of age) who are receiving for chronic hypoparathyroidism any of the following options: standard therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone.
•2. Pediatric participants (less than \[\<\] 18 years of age) who are receiving for chronic hypoparathyroidism any of the following options: standard therapy, standard therapy plus rhPTH(1-84), or rhPTH(1-84) therapy alone.

Exclusion Criteria

•Participants or legally acceptable representatives unable to provide informed consent.
•Participants using rhPTH(1-34) or who used rhPTH(1-34) for more than 2 years are excluded. Participants who had been treated with rhPTH(1-34) within 3 months of enrollment are also excluded as are participants currently using rhPTH(1-34).
•FOR US SITES ONLY: Participants treated with rhPTH(1-84) prior to the US recall may use rhPTH(1-34) only while rhPTH(1-84) is unavailable due to the recall.
•Participants currently enrolled in an interventional clinical study (whether or not the study is related to hypoparathyroidism); note that this does not include participants enrolled in other observational registries.
•History of hypoparathyroidism resulting from impaired responsiveness to PTH (pseudohypoparathyroidism).

Locations (100)

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of Arizona Medical Center

Tucson, Arizona, United States

Children's Hospital Los Angeles

Los Angeles, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

Dr. Joselito Cabaccan

San Jose, California, United States

University of Colorado Hospital

Aurora, Colorado, United States

Yale University

New Haven, Connecticut, United States

Hanson Clinical Research Center

Port Charlotte, Florida, United States

Thyroid & Endocrine Center of Florida

Sarasota, Florida, United States

East-West Medical Research Institute

Honolulu, Hawaii, United States

Key Dates

Start Date

July 30, 2013

Primary Completion Date

November 30, 2034

Completion Date

November 30, 2034

Last Updated

September 29, 2025

Enrollment

1,339

ACTUAL participants

Conditions

Hypoparathyroidism

Interventions

No intervention

OTHER

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT07345494

Hypoparathyroidism

View study

RECRUITINGPHASE1/PHASE2

Parathyroid Allotransplant for Treatment of Hypoparathyroidism

NCT06961071

HypoparathyroidismHypoparathyroidism Postprocedural+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Registry for Participants With Chronic Hypoparathyroidism

Inclusion Criteria

Exclusion Criteria

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Parathyroid Allotransplant for Treatment of Hypoparathyroidism

Hypoparathyroidism Natural History Study

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

PTeye vs Surgeons Eyes in Intraoperative Identification and Functional Preservation of Parathyroid Glands During Thyroid Surgery: A Parallel Randomized Controlled Clinical Trial.

Parathyroid Allotransplant for Severe Refractory Hypoparathyroidism